A pilot study of barriers to medication adherence in schizophrenia

Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, VA Medical Center (152/NLR), 2200 Ft. Roots Drive, North Little Rock, AR 72114-1706, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 02/2004; 65(2):211-6. DOI: 10.4088/JCP.v65n0211
Source: PubMed

ABSTRACT Interventions to improve adherence to antipsychotic medication are needed. The aims of the current study were to identify the most common barriers to medication adherence in a cohort of patients receiving outpatient and inpatient treatment for an acute exacerbation of schizophrenia, compare clinical and demographic characteristics of patients with lower versus higher numbers of barriers, and characterize patients most likely to be nonadherent to antipsychotic medication.
The present study analyzed data collected during the Schizophrenia Guidelines Project (SGP), a multisite study of strategies to implement practice guidelines that was funded by the U.S. Department of Veterans Affairs and conducted from March 1999 to October 2000. Nurse coordinators had conducted clinical assessments and performed an intervention designed to improve medication adherence by addressing barriers to adherence. Data on patient symptoms, functioning, and side effects had been obtained using the Positive and Negative Syndrome Scale (PANSS), the Schizophrenia Outcomes Module, the Medical Outcomes Study 36-item Short-Form Health Survey, and the Barnes Akathisia Scale (BAS). Administrative data were used to identify patients with an ICD-9 code for schizophrenia. A total of 153 patients who met this criterion and participated in the intervention arm of the SGP had complete data available for analysis in the current study.
The most common patient-reported barriers were related to the stigma of taking medications, adverse drug reactions, forgetfulness, and lack of social support. Bivariate analysis showed that patients with high barriers were significantly more likely to be nonadherent (p < or =.02), to have problems with alcohol or drug use (p =.02), to have higher PANSS total scores (p =.03), and to have higher mean BAS scores (p =.02). Logistic regression showed that lower patient education level (odds ratio [OR] = 3.95, p =.02), substance abuse (OR = 3.24, p =.01), high PANSS total scores (OR = 1.02, p =.05), and high barriers (OR = 2.3, p =.05) were significantly associated with the probability of nonadherence.
It may be possible to identify patients most likely to benefit from adherence intervention. The data presented here will help to inform future research of clinical interventions to improve medication adherence in schizophrenia and help to stimulate further work in this area.

  • Source
    • "The most wellestablished reasons pertain to lack of insight (David, 1992; Kemp and David, 1995), medication side-effects or non response and poor therapeutic alliance (Byerly et al., 2007; Miller, 2008). Less well researched factors that have been added to this enumeration relate to psychological motives such as fear/avoidance of stigma (Hudson et al., 2004; Tranulis et al., 2011) and cognitive factors such as forgetfulness (Moritz et al., 2013; Moritz et al., 2009) and denial that biological factors are relevant to the disorder (Wiesjahn et al., 2014). Few studies addressed whether positive attitudes towards psychopathological symptoms may also play a role in nonadherence . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 50%–75% of all patients do not take their antipsychotic medication as prescribed. The current study examined reasons why patients continue versus discontinue antipsychotic medication. We were particularly interested to which extent positive attitudes towards psychotic symptoms foster medication nonadherence. An anonymous online questionnaire was set up to decrease response biases. After a strict selection process, 91 participants with schizophrenia spectrum disorders were retained for the final analyses. On average, 6.2 different reasons for nonadherence were reported. Side-effects (71.4%), sudden subjective symptom improvement (52.4%), forgetfulness (33.3%) and poor communication between therapist and patient (25.6%) emerged as the most frequent reasons for drug discontinuation. Approximately one fourth of all participants (27.3%) reported at least one positive aspect of psychosis as a reason for nonadherence. In contrast, patients reported on average 3.5 different reasons for adherence (e.g., want to live a normal life (74.6%), fear of psychotic symptoms (49.3%)). The belief that paranoia represents a survival strategy (subscale derived from the Beliefs about Paranoia Scale) was significantly associated with nonadherence. Patients' attitudes toward medication and the individual illness model need to be carefully considered when prescribing medication. In particular, for patients who likely discontinue psychopharmacological treatment, complementary or alternative psychological treatment should be sought in view of a largely increased relapse rate in case of sudden drug discontinuation.
    European Neuropsychopharmacology 11/2014; 24(11). DOI:10.1016/j.euroneuro.2014.09.008 · 5.40 Impact Factor
  • Source
    • "Some of the participants in that study related that the likelihood of adherence would have been larger if they early on had been honestly informed that the need for medication might be life-long. Patients in an earlier pilot study considered that the stigma of taking antipsychotics was the main barrier to adherence (Hudson et al., 2004). Others found that patients with employment had a more negative drug attitude and ran an increased risk of non-adherence, possibly connected to the stigma of having to take antipsychotics to function, and the drawback of simultaneously suffering from debilitating side effects (Freudenreich et al., 2004; Hofer et al., 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aims of this naturalistic non-interventional study were to quantify the level of stigma and discrimination in persons with schizophrenia and to test for potential associations between different types of stigma and adherence to antipsychotics. Antipsychotic medication use was electronically monitored with a Medication Event Monitoring System (MEMS(®)) for 12 months in 111 outpatients with schizophrenia and schizophrenia-like psychosis (DSM-IV). Stigma was assessed at endpoint using the Discrimination and Stigma Scale (DISC). Single DISC items that were most frequently reported included social relationships in making/keeping friends (71%) and in the neighborhood (69%). About half of the patients experienced discrimination by their families, in intimate relationships, regarding employment and by mental health staff. Most patients (88%) wanted to conceal their mental health problems from others; 70% stated that anticipated discrimination resulted in avoidance of close personal relationships. Non-adherence (MEMS(®) adherence≤0.80) was observed in 30 (27.3%). When DISC subscale scores (SD) were entered in separate regression models, neither experienced nor anticipated stigma was associated with adherence. Our data do not support an association between stigma and non-adherence. Further studies in other settings are needed as experiences of stigma and levels of adherence and their potential associations might vary by a healthcare system or cultural and sociodemographic contexts. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    Psychiatry Research 10/2014; 220(3):811-817. DOI:10.1016/j.psychres.2014.10.016 · 2.68 Impact Factor
  • Source
    • "Research suggests that limitations of treatment, such as side effects of medication, are a key reason for nonadherence to treatment (e.g., Brown et al., 2005; Hudson et al., 2004; McCann et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We described physician usage of persuasive strategies pertaining to four dimensions of medical recommendations given during naturally occurring clinical visits-problem seriousness, treatment effectiveness, patient's self-efficacy, and potential limitations with the recommended treatment. We then examined the impact of these strategies on patient satisfaction and intention to follow physicians' medical advice. An analysis was conducted of 187 transcripts of audio-recorded outpatient visits during which a new medication was prescribed, augmented with patient and physician surveys. Two-hundred forty-two cases of new medication prescription were identified, and each case was coded into categories describing physicians' prescription-giving behaviors. In most cases, physicians addressed only one or two of the four dimensions of medical recommendations when they were prescribing new medications to their patients. In about one-third of visits, none of the four dimensions was addressed. However, physician use of persuasive strategies pertaining to the four dimensions did not appear to have any significant impact on patients' satisfaction with the visit or intention to follow their doctor's advice. The implications of the findings are discussed in light of the study's limitations and directions for future research.
    Health Communication 03/2011; 26(3):286-96. DOI:10.1080/10410236.2010.550020 · 0.97 Impact Factor
Show more